Clinical Trials
3 trialsNCT07134556 2026-05-01
ADJUNCT
MedSIR
Phase 2 Withdrawn
NCT07328490 2026-04-28
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT02161679 2021-08-19
Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Gilead Sciences
Phase 2 Withdrawn